Clinical trials: Glial Tumor
Brain Cancer
Precision Radiotherapy Enabled by Molecular MRI
This is a research study to determine if a novel molecular magnetic resonance imaging (MRI) technique, called amide proton transfer (APT) imaging, is useful in identifying the most aggressive areas of tumor needed for…
- Trial name
- NCT07512154
- Testing
- Amide proton transfer radiotherapy, Standard radiotherapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma Multiforme (GBM)
CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM
This study is for patients that have a type of brain cancer called glioblastoma multiforme (GBM). The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers.
- Trial name
- HERT-GBM (NCT01109095)
- Testing
- HER.CAR CMV-specific CTLs
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Baylor College of Medicine
CNS Embryonal Tumor, CNS, Medulloblastoma
Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
Pilot study to determine feasibility of adding intrathecal chemotherapy and maintenance therapy after high dose chemotherapy for treatment of newly diagnosed HR-EBTs in patients less than 6 years of age.
- Conditions
- CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor, Medulloblastoma, Childhood
- Trial name
- NCT06942039
- Testing
- Cytarabine IT, hydrocortisone, Cisplatin
- Where
- 12 sites in Canada
- Volunteers
- 15 people
- Sponsor
- C17 Council
Advanced Solid Malignancies
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that…
- Trial name
- CERTIS1 (NCT05417594)
- Testing
- AZD9574, Temozolomide (TMZ), [11C]AZ1419 3391
- Where
- 32 sites in United States, Australia and 5 more
- Volunteers
- 695 people
- Sponsor
- AstraZeneca
Glioblastoma
Efficacy of Distant Healing in Glioblastoma Treatment
This study will assess whether distant healing effects survival time and loss of function for glioblastoma patients.
- Trial name
- NCT00029783
- Testing
- Distant Healing
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Glioblastoma, Meningeal Arteries
Research on the Safety and Efficacy of Blocking Dural Blood Supply in Glioblastoma Patients
Glioblastoma is the most common primary malignancy of the central nervous system with a very poor prognosis. Most of the immunotherapies that have made significant breakthroughs in the treatment of other tumors in recent years…
- Trial name
- NCT05990556
- Testing
- interventional procedure to block bilateral meningeal blood supply
- Where
- China
- Volunteers
- 20 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Brain Neoplasms, Glioma
A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors
The presence of a highly selective blood-brain barrier (BBB) at the level of the brain capillary endothelium prevents chemotherapeutic agents from attaining therapeutic concentrations at the target site.
- Conditions
- Brain Neoplasms, Glioma, Medulloblastoma
- Trial name
- NCT00001502
- Testing
- RMP-7 and carboplatin
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Relapsed Solid Tumor, Refractory Solid Tumor
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
Phase 1: To confirm the safety and anticipated recommended phase 2 dose (RP2D) of REGN2810 (cemiplimab) for children with recurrent or refractory solid or Central Nervous System (CNS) tumors To characterize the pharmacokinetics…
- Conditions
- Relapsed Solid Tumor, Refractory Solid Tumor, Relapsed Central Nervous System Tumor, Refractory Central Nervous System Tumor
- Trial name
- NCT03690869
- Testing
- cemiplimab (monotherapy), cemiplimab (maintenance), Conventional or hypofractionated
- Where
- 20 sites in United States
- Volunteers
- 57 people
- Sponsor
- Regeneron Pharmaceuticals
Low Grade Glioma
Ovarian Aging in Low Grade Glioma (LGG) Treated With Temozolomide
The purpose of this study is to look at how a chemotherapy treatment (Temozolomide, also called Temodar) affects the process of ovarian aging which is measured by a decline in ovarian follicle count, in patients with Low Grade…
- Trial name
- OVA-LGG (NCT01452854)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of California, San Francisco
Glioblastoma, Gliosarcoma
Radiosurgery Plus Bevacizumab in Glioblastoma
RATIONALE: Radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Conditions
- Glioblastoma, Gliosarcoma, Brain Tumor
- Trial name
- NCT01086345
- Testing
- radiosurgery, bevacizumab, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Case Comprehensive Cancer Center
Low Grade Glioma of Brain
Surgical Management of Low Grade Glioma
To assess the morbidity and mortality in low grade glioma patients following surgical management.
- Trial name
- NCT06499922
- Testing
- SURGICAL EXCISION
- Volunteers
- 100 people
- Sponsor
- Assiut University
Glioblastoma, Anaplastic Astrocytoma
BNCT to Treat Glioma That Has Progressed Following Radiotherapy
Boron Neutron Capture Therapy (BNCT) is an experimental radiation therapy technique which is based on the principle of irradiating boron atoms with neutrons.
- Trial name
- NCT00115440
- Testing
- Bononophenylalanine (BPA)-based BNCT
- Where
- Finland
- Volunteers
- 22 people
- Sponsor
- Boneca Corporation
Glioma
Use of Pulsed Low-dose Rate Re-irradiation for Recurrent Glioma (PULSAR)
Re-irradiation in gliomas is a therapeutic option at recurrence before of 2nd-line chemotherapy. The dose of re-irradiation with conventional fractionation is unfortunately limited by the risk of symptomatic radionecrosis that is…
- Trial name
- PULSAR (NCT06055517)
- Testing
- Pulsed low dose-rate radiotherapy (pLDRT)
- Where
- Italy
- Volunteers
- 29 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Glioma
Awake Intraoperative Language Mapping and Chinese Probabilistic Map Construction
The study aims at constructing a Chinese language probabilistic map by awake intraoperative direct electrical stimulation (DES) language mapping.
- Trial name
- NCT03641391
- Testing
- Intraoperative direct cortical electrical stimulation, Intraoperative direct subcortical electrical stimulation
- Where
- 3 sites in China
- Volunteers
- 300 people
- Sponsor
- Huashan Hospital
Glioma of Brain, CAR-T Cell Immunotherapy
CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in treating with GD2 positive glioma patients.
- Trial name
- NCT04406610
- Testing
- GD2 CAR-T immunotherapy
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Brain and Central Nervous System Tumors
Vaccine Therapy in Treating Young Patients Who Are Undergoing Surgery for Malignant Glioma
RATIONALE: Vaccines made from a person's white blood cells and tumor cells may help the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00107185
- Testing
- therapeutic autologous dendritic cells
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Glioma
IL13Rα2 CAR-T for Patients With r/r Glioma
This is a dose exploration clinical trial to assess the safety and feasibility of the IL13Ra2-targeted CAR-T in glioma.
- Trial name
- ENHANCING (NCT06355908)
- Testing
- IL13Rα2 CAR-T
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Yang Zhang
Brain Cancer, Brain Stem Tumors
Phase I Rindopepimut After Conventional Radiation in Children w/ Diffuse Intrinsic Pontine Gliomas
This is a research study of patients with diffuse intrinsic pontine gliomas. We hope to learn about the safety and efficacy of treating pediatric diffuse intrinsic pontine glioma patients with the EGFRvIII peptide vaccine after…
- Conditions
- Brain Cancer, Brain Stem Tumors, Pontine Tumors
- Trial name
- NCT01058850
- Testing
- Rindopepimut
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Paul Graham Fisher
Central Nervous System Tumor
Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System
The purpose of this study is to examine the use of a single dose of tozuleristide (24 or 36 mg) and the Canvas imaging system during surgical resection of primary central nervous system (CNS) tumors: Primary gadolinium enhancing…
- Trial name
- NCT04743310
- Testing
- tozuleristide, Canvas imaging system, Surgical resection of tumor
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- John Yu
Brain Stem Glioma, Cerebral Astrocytoma
Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma
This randomized phase II/III trial is studying vorinostat, temozolomide, or bevacizumab to see how well they work compared with each other when given together with radiation therapy followed by bevacizumab and temozolomide in…
- Conditions
- Brain Stem Glioma, Cerebral Astrocytoma, Childhood Cerebellar Anaplastic Astrocytoma, Childhood Cerebral Anaplastic Astrocytoma
- Trial name
- NCT01236560
- Testing
- Bevacizumab, Temozolomide, Vorinostat
- Where
- 132 sites in United States, Canada
- Volunteers
- 101 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.